296 research outputs found

    One pot synthesis of a stable and cost effective silver particle free ink for inkjet printed flexible electronics

    Get PDF
    Silver particle free inks display immense superiority and potential over silver nanoparticle based inks in the aspect of synthesis, flexibility and low temperature processing, which has attracted considerable research interest as an alternative for fabricating conductive structures in recent years. Although recent research on silver particle free inks has led to beneficial results, there are still some drawbacks some of the inks are chemically unstable and hence are not suitable for industrial inkjet printing process, although they have good conductivity; while others are cheap in terms of raw material costs but are complicated to make due to the complex synthetic route or using hazardous procedures, or are not compatible with inkjet printing. Therefore, it will be advantageous to develop a stable, cheap and inkjet printable silver particle free ink using a simple synthetic procedure. Alcohols are favorable solvents for silver particle free inks that can provide the ink with essential fluid properties for inkjet printing. However, they have some negative effects on the ink performance due to their physicochemical properties, which should be avoided. In this work, a simple do it yourself silver particle free ink is presented, which shows high chemical stability, low cost and good printability. The ink is formulated via a simple silver oxalate precursor route in alcohols. The fluid property, thermal property, stability and electrical performance of the inks based on different alcohols were investigated and optimized to obtain the final ink for printing on glass and flexible polyimide substrates. The printed Ag features yielded a resistivity of 15.46 amp; 956; amp; 937; cm at a sintering temperature of 180 C, which is equivalent to 10 times bulk silver. Based on a comprehensive assessment, we can offer a low cost, easy to make, reliable and highly competitive ink for flexible printed electronic

    Finally, inkjet printed metal halide perovskite LEDs utilizing seed crystal templating of salty PEDOT PSS

    Get PDF
    Solution processable metal halide perovskites are increasingly implemented in perovskite based light emitting diodes PeLEDs . Especially green PeLEDs based on methylammonium lead bromide MAPbBr3 composites exhibit impressive optoelectronic properties, while allowing processing by low cost and upscalable printing methods. In this study, we have investigated the influence of potassium chloride KCl blended into the common hole injection material poly 3,4 ethylenedioxythiophene polystyrene sulfonate PEDOT PSS to boost PeLED device performance. The inclusion of KCl firstly results in a change in morphology of the PEDOT PSS layer, which then acts as a template during deposition of the perovskite layer. A MAPbBr3 polyethylene glycol PEG composite was used, which does not require the deposition of an anti solvent droplet to induce preferential perovskite crystallization and is therefore suitable for spin coating and scalable inkjet printing processes. PeLEDs utilizing the KCl induced templating effect on a planar PEDOT PSS MAPbBr3 PEG architecture show improved performance, predominantly due to improved crystallization. PeLEDs incorporating spin coated perovskite layers yield a 40 fold increase in luminance 8000 cd m 2 while the turn on voltage decreases to 2.5 V. KCl modified PEDOT PSS contact layers enabled the realization of inkjet printed PeLEDs with luminance increased by a factor of 20 at a maximum of 4000 cd m 2 and a turn on voltage of 2.5 V. This work paves the way for inkjet printed perovskite light emitting devices for a wide variety of low cost and customizable application

    Infrared spectroscopy of phytochrome and model pigments

    Get PDF
    Fourier-transform infrared difference spectra between the red-absorbing and far-red-absorbing forms of oat phytochrome have been measured in H2O and 2H2O. The difference spectra are compared with infrared spectra of model compounds, i.e. the (5Z,10Z,15Z)- and (5Z,10Z,15E)-isomers of 2,3,7,8,12,13,17,18-octaethyl-bilindion (Et8-bilindion), 2,3-dihydro-2,3,7,8,12,13,17,18-octaethyl-bilindion (H2Et8-bilindion), and protonated H2Et8-bilindion in various solvents. The spectra of the model compounds show that only for the protonated forms can clear differences between the two isomers be detected. Since considerable differences are present between the spectra of Et8-bilindion and H2Et8-bilindion, it is concluded that only the latter compound can serve as a model system of phytochrome. The 2H2O effect on the difference spectrum of phytochrome supports the view that the chromophore in red-absorbing phytochrome is protonated and suggests, in addition, that it is also protonated in far-red-absorbing phytochrome. The spectra show that protonated carboxyl groups are influenced. The small amplitudes in the difference spectra exclude major changes of protein secondary structure

    Gas flow assisted vacuum drying Identification of a novel process for attaining high quality perovskite films

    Get PDF
    Controlling the nucleation and crystal growth in solution processed metal halide perovskite MHP thin films is the pivotal point in fabricating homogenous and pinhole free films. Using scalable coating and printing techniques, vacuum and gas flow assisted drying processes turn out to be the most promising methods to induce nucleation and crystallization. Yet, the exact interplay and nature of these processes are unclear. In our work, we optically monitor these processes in situ. For the first time, we can show that a controlled venting of the vacuum chamber and the use of a subsequent gas flow are key to achieve homogenous nucleation. Utilizing this gas flow assisted vacuum drying process, we find that regular, optically dense and pinhole free MHP layers can be fabricated via inkjet printing, which yield solar cells with a power conversion efficiency of 16 , as compared to 4.5 for vacuum dryin

    Combinatorial inkjet printing for compositional tuning of metal halide perovskite thin films

    Get PDF
    To accelerate the materials discovery and development process for a sustainable technology advancement it is imperative to explore and develop combined high throughput material synthesis and analysis workflows. In this work, we investigate a method of combinatorial inkjet printing to tune the composition of the inorganic cesium lead mixed halide perovskite solid solution, CsPb BrxI1 amp; 8722;x 3. The compositional variation is achieved by simultaneous printing of different precursor inks with multiple printheads and controlled by varying the number of droplets printed by each printhead throughout the sample. The droplet placement is optimised through an algorithm that allows maximum mixing of the combined inks. The local compositional homogeneity of thin film samples was investigated as a function of the printing resolution by micrometer resolution X ray fluorescence and synchrotron based grazing incidence wide angle X ray scattering. We show that a combinatorial library of ten compositions between CsPbI3 and CsPbBr2I, printed using the developed algorithm, is locally homogeneous for the optimised printing parameters. An implementation of the algorithm in the high level programming language Python is provided for easy use in other system

    An open-access database and analysis tool for perovskite solar cells based on the FAIR data principles

    Get PDF
    Large datasets are now ubiquitous as technology enables higher-throughput experiments, but rarely can a research field truly benefit from the research data generated due to inconsistent formatting, undocumented storage or improper dissemination. Here we extract all the meaningful device data from peer-reviewed papers on metal-halide perovskite solar cells published so far and make them available in a database. We collect data from over 42,400 photovoltaic devices with up to 100 parameters per device. We then develop open-source and accessible procedures to analyse the data, providing examples of insights that can be gleaned from the analysis of a large dataset. The database, graphics and analysis tools are made available to the community and will continue to evolve as an open-source initiative. This approach of extensively capturing the progress of an entire field, including sorting, interactive exploration and graphical representation of the data, will be applicable to many fields in materials science, engineering and biosciences

    Rare and Frequent Promoter Methylation, Respectively, of TSHZ2 and 3 Genes That Are Both Downregulated in Expression in Breast and Prostate Cancers

    Get PDF
    Neoplastic cells harbor both hypomethylated and hypermethylated regions of DNA. Whereas hypomethylation is found mainly in repeat sequences, regional hypermethylation has been linked to the transcriptional silencing of certain tumor suppressor genes. We attempted to search for candidate genes involved in breast/prostate carcinogenesis, using the criteria that they should be expressed in primary cultures of normal breast/prostate epithelial cells but are frequently downregulated in breast/prostate cancer cell lines and that their promoters are hypermethylated.We identified several dozens of candidates among 194 homeobox and related genes using Systematic Multiplex RT-PCR and among 23,000 known genes and 23,000 other expressed sequences in the human genome by DNA microarray hybridization. An additional examination, by real-time qRT-PCR of clinical specimens of breast cancer, further narrowed the list of the candidates. Among them, the most frequently downregulated genes in tumors were NP_775756 and ZNF537, from the homeobox gene search and the genome-wide search, respectively. To our surprise, we later discovered that these genes belong to the same gene family, the 3-member Teashirt family, bearing the new names of TSHZ2 and TSHZ3. We subsequently determined the methylation status of their gene promoters. The TSHZ3 gene promoter was found to be methylated in all the breast/prostate cancer cell lines and some of the breast cancer clinical specimens analyzed. The TSHZ2 gene promoter, on the other hand, was unmethylated except for the MDA-MB-231 breast cancer cell line. The TSHZ1 gene was always expressed, and its promoter was unmethylated in all cases.TSHZ2 and TSHZ3 genes turned out to be the most interesting candidates for novel tumor suppressor genes. Expression of both genes is downregulated. However, differential promoter methylation suggests the existence of distinctive mechanisms of transcriptional inactivation for these genes

    An open-access database and analysis tool for perovskite solar cells based on the FAIR data principles

    Get PDF
    Large datasets are now ubiquitous as technology enables higher-throughput experiments, but rarely can a research field truly benefit from the research data generated due to inconsistent formatting, undocumented storage or improper dissemination. Here we extract all the meaningful device data from peer-reviewed papers on metal-halide perovskite solar cells published so far and make them available in a database. We collect data from over 42, 400 photovoltaic devices with up to 100 parameters per device. We then develop open-source and accessible procedures to analyse the data, providing examples of insights that can be gleaned from the analysis of a large dataset. The database, graphics and analysis tools are made available to the community and will continue to evolve as an open-source initiative. This approach of extensively capturing the progress of an entire field, including sorting, interactive exploration and graphical representation of the data, will be applicable to many fields in materials science, engineering and biosciences. © 2021, The Author(s)

    Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

    Get PDF
    Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.
    corecore